Literature DB >> 29568948

Overexpression of collagen type V α1 chain in human breast invasive ductal carcinoma is mediated by TGF-β1.

Weimin Ren1, Youyuan Zhang2, Lingyun Zhang1, Qunbo Lin1, Jinguo Zhang1, Guoxiong Xu1.   

Abstract

Collagen type V α1 chain (COL5A1) is a minor fibrillar collagen in mammals that co-polymerizes with type I collagen to adjust the diameter of collagen molecules. However, the function of COL5A1 in invasive ductal carcinoma (IDC) of the human breast remains unknown. In the present study, our group examined the expression of COL5A1 in IDC compared with its adjacent normal tissue and fibroadenoma of the breast. COL5A1 was revealed to be overexpressed in IDC compared with benign tumor and adjacent normal control tissues, and was associated with the expression of estrogen receptor and progesterone receptor. No association between COL5A1 expression and tumor size, lymph node metastasis, clinical stage, age, or Her2 expression was identified. High expression of COL5A1 mRNA was associated with distant metastasis free survival in patients with breast cancer. Knockdown of COL5A1 led to a decrease of cell viability, as detected by the WST-1 assay, and an inhibition of migration and invasion, as detected by wound healing and Transwell assays, respectively, in the breast cancer cell line MCF-7. The expression of COL5A1 in MCF-7 cells was downregulated by transforming growth factor (TGF)‑β1, which was abolished in the presence of SB-431542, an inhibitor of TGF-β type I receptor. In conclusion, these data indicated that COL5A1 is overexpressed in IDC and regulated by TGF-β1, suggesting that an increase of COL5A1 reflects tumor progression and may serve as a novel biomarker and therapeutic target for the treatment of breast IDC.

Entities:  

Year:  2018        PMID: 29568948     DOI: 10.3892/ijo.2018.4317

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  8 in total

1.  The new identified biomarkers determine sensitivity to immune check-point blockade therapies in melanoma.

Authors:  Hao Chen; Meng Yang; Qinghua Wang; Fengju Song; Xiangchun Li; Kexin Chen
Journal:  Oncoimmunology       Date:  2019-05-10       Impact factor: 8.110

2.  Molecular alterations due to Col5a1 haploinsufficiency in a mouse model of classic Ehlers-Danlos syndrome.

Authors:  Keren Machol; Urszula Polak; Monika Weisz-Hubshman; I-Wen Song; Shan Chen; Ming-Ming Jiang; Yuqing Chen-Evenson; Mary Ann E Weis; Douglas R Keene; David R Eyre; Brendan H Lee
Journal:  Hum Mol Genet       Date:  2022-04-22       Impact factor: 5.121

3.  Pyridoxine 5'-phosphate oxidase is correlated with human breast invasive ductal carcinoma development.

Authors:  Weimin Ren; Wencai Guan; Jinguo Zhang; Fanchen Wang; Guoxiong Xu
Journal:  Aging (Albany NY)       Date:  2019-04-14       Impact factor: 5.682

4.  Tanshinone IIA reverses EGF- and TGF-β1-mediated epithelial-mesenchymal transition in HepG2 cells via the PI3K/Akt/ERK signaling pathway.

Authors:  Longkai Zhang; Weibin Lin; Xiaodan Chen; Gang Wei; Hailong Zhu; Shangping Xing
Journal:  Oncol Lett       Date:  2019-11-01       Impact factor: 2.967

5.  The Hypoxia-Related Gene COL5A1 Is a Prognostic and Immunological Biomarker for Multiple Human Tumors.

Authors:  Hua Zhu; Xinyao Hu; Shi Feng; Zhihong Jian; Ximing Xu; Lijuan Gu; Xiaoxing Xiong
Journal:  Oxid Med Cell Longev       Date:  2022-01-17       Impact factor: 6.543

6.  Prospective molecular mechanism of COL5A1 in breast cancer based on a microarray, RNA sequencing and immunohistochemistry.

Authors:  Mei Wu; Qi Sun; Chao-Hua Mo; Jin-Shu Pang; Jia-Yin Hou; Ling-Ling Pang; Hui-Ping Lu; Yi-Wu Dang; Su-Jie Fang; Deng Tang; Gang Chen; Zhen-Bo Feng
Journal:  Oncol Rep       Date:  2019-05-03       Impact factor: 3.906

7.  Overexpression of COL5A1 promotes tumor progression and metastasis and correlates with poor survival of patients with clear cell renal cell carcinoma.

Authors:  Gang Feng; Hui-Min Ma; Hou-Bao Huang; Ya-Wei Li; Peng Zhang; Jian-Jun Huang; Long Cheng; Guo-Rong Li
Journal:  Cancer Manag Res       Date:  2019-02-07       Impact factor: 3.989

8.  In-depth characterization of a new patient-derived xenograft model for metaplastic breast carcinoma to identify viable biologic targets and patterns of matrix evolution within rare tumor types.

Authors:  M D Matossian; T Chang; M K Wright; H E Burks; S Elliott; R A Sabol; H Wathieu; G O Windsor; M S Alzoubi; C T King; J B Bursavich; A M Ham; J J Savoie; K Nguyen; M Baddoo; E Flemington; O Sirenko; E F Cromwell; K L Hebert; F Lau; R Izadpanah; H Brown; S Sinha; J Zabaleta; A I Riker; K Moroz; L Miele; A H Zea; A Ochoa; B A Bunnell; B M Collins-Burow; E C Martin; M E Burow
Journal:  Clin Transl Oncol       Date:  2021-08-09       Impact factor: 3.405

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.